LTRN Lantern Pharma Forecast, Technical & Fundamental Analysis
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform... Show more
LTRN is expected to report earnings to rise 5.56% to -37 cents per share on August 12
Q2'26
Est.
$-0.38
Q4'25
Beat
by $0.18
Q3'25
Beat
by $0.05
Q2'25
Beat
by $0.13
Q4'24
Beat
by $0.05
The last earnings report on March 30 showed earnings per share of -36 cents, beating the estimate of -54 cents. With 67.77K shares outstanding, the current market capitalization sits at 44.15M.
A.I. Advisor
published General Information
General Information
a company, which engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data
A.I.dvisor indicates that over the last year, LTRN has been loosely correlated with ALZN. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if LTRN jumps, then ALZN could also see price increases.
Momentum Indicator for LTRN turns negative, indicating new downward trend
LTRN saw its Momentum Indicator move below the 0 level on July 07, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In of the 95 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for LTRN moved out of overbought territory on June 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator moved out of overbought territory. In of the 18 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for LTRN turned negative on June 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LTRN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
LTRN moved above its 50-day moving average on July 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for LTRN moved above the 200-day moving average on July 06, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LTRN advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .
LTRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 91 cases where LTRN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LTRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.804) is normal, around the industry mean (22.885). P/E Ratio (0.000) is within average values for comparable stocks, (37.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.508). LTRN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (434.181).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LTRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
